Research
Hormonal
Specific microRNAs (e.g., miR-143, miR-145, miR-27a, miR-130a) regulate adipogenesis (fat cell formation) and insulin sensitivity, with some promoting and others inhibiting fat cell differentiation and glucose homeostasis.
The formation of new fat cells is tightly controlled by specific microRNAs. Some miRNAs encourage fat storage (like miR-143), while others prevent it (like miR-27a). This biological regulation explains why fat distribution and insulin sensitivity vary significantly between individuals.
ModerateQualifiesMEDIUM confidence
miR-143 and miR-145 are often investigated together... miR-143 has been identified as a positive regulator of human adipocyte differentiation acting via ERK5 signaling... On the contrary, mice lacking for the miR-143–145 cluster did not develop the obesity-associated insulin resistance.
Why this rating
Based on animal models and in vitro studies; human data is observational.
Source
Role of microRNAs in obesity and obesity-related diseases
Giuseppe Iacomino et al. · Genes & Nutrition · 2017
DOI 10.1186/s12263-017-0577-z
narrative_reviewCited 223×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dysregulation of specific microRNAs (miRNAs) in adipose tissue, pancreas, liver, and muscle contributes to the pathogenesis of obesity and related metabolic diseases by altering gene expression involved in energy balance, insulin signaling, and inflammation.Moderate
- Circulating microRNAs (miRNAs) found in plasma and other body fluids can serve as biomarkers for obesity and metabolic diseases, and may act as endocrine signaling molecules mediating inter-organ communication.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →